Literature DB >> 19539085

Relation of body mass index to mortality after development of heart failure due to acute coronary syndrome.

Audrey H Wu1, Kim A Eagle, Daniel G Montgomery, Eva Kline-Rogers, Yu-Chen Hu, Keith D Aaronson.   

Abstract

Several studies have suggested that obesity may be associated with a survival advantage in heart failure (HF). The duration of HF likely influences disease severity and may introduce lead-time bias into analyses of outcomes. The aim of this study was to analyze a cohort in which the exact time of HF onset could be determined: patients in the University of Michigan subset of the acute coronary syndromes (ACS) database of the Global Registry of Acute Coronary Events (GRACE) who developed new-onset HF (no history of HF and left ventricular ejection fraction <or=40% or qualitatively diminished) with their index ACS events from January 1999 to March 2006 (n = 446). For analysis, body mass index (BMI) was categorized as normal (18.5 to <25 kg/m(2)), overweight (25 to <30 kg/m(2)), and obese (>or=30 kg/m(2)). Underweight patients (BMI <or=18.5 kg/m(2)) were excluded. Separate multivariate Cox regression models were performed to examine the effect of BMI group and other potential confounders on all-cause mortality and on the combined outcome of all-cause death, cardiac transplantation, or ventricular assist device implantation. BMI groups were not associated with different risks for the combined outcome, although overweight BMI approached statistical significance for lower risk for the combined outcome. Overweight BMI was significantly associated with lower risk for all-cause death (hazard ratio 0.63, 95% confidence interval 0.42 to 0.94, p = 0.02), although obese BMI was not (hazard ratio 1.06, 95% confidence interval 0.69 to 1.64, p = 0.8). In conclusion, these findings suggest a U-shaped relation between mortality and BMI in the setting of new-onset HF after ACS.

Entities:  

Mesh:

Year:  2009        PMID: 19539085     DOI: 10.1016/j.amjcard.2009.02.026

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Body mass index and mortality in acute myocardial infarction patients.

Authors:  Emily M Bucholz; Saif S Rathore; Kimberly J Reid; Philip G Jones; Paul S Chan; Michael W Rich; John A Spertus; Harlan M Krumholz
Journal:  Am J Med       Date:  2012-04-05       Impact factor: 4.965

2.  Body mass index and rest myocardial perfusion defect predicts cardiac death in patients with chronic heart failure.

Authors:  Min Cai; Feng Wang; Jian Zhang; Zuo-Xiang He
Journal:  Int J Cardiovasc Imaging       Date:  2012-02-12       Impact factor: 2.357

3.  Reverse J-shaped relationship between body mass index and in-hospital mortality of patients hospitalized for heart failure in Japan.

Authors:  Hidetaka Itoh; Hidehiro Kaneko; Hiroyuki Kiriyama; Tatsuya Kamon; Katsuhito Fujiu; Kojiro Morita; Haruki Yotsumoto; Nobuaki Michihata; Taisuke Jo; Norifumi Takeda; Hiroyuki Morita; Hideo Yasunaga; Issei Komuro
Journal:  Heart Vessels       Date:  2020-09-27       Impact factor: 2.037

4.  Inverse association between central obesity and arterial stiffness in Korean subjects with metabolic syndrome: a cross-sectional cohort study.

Authors:  Ki-Bum Won; Hyuk-Jae Chang; Hiroyuki Niinuma; Koichiro Niwa; Kyewon Jeon; In-Jeong Cho; Chi-Young Shim; Geu-Ru Hong; Namsik Chung
Journal:  Diabetol Metab Syndr       Date:  2015-01-27       Impact factor: 3.320

5.  Inverse relationship of cardioankle vascular index with BMI in healthy Japanese subjects: a cross-sectional study.

Authors:  Daiji Nagayama; Haruki Imamura; Yuta Sato; Takashi Yamaguchi; Noriko Ban; Hidetoshi Kawana; Masahiro Ohira; Atsuhito Saiki; Kohji Shirai; Ichiro Tatsuno
Journal:  Vasc Health Risk Manag       Date:  2016-12-21

6.  The presence of obesity paradox in Greek patients with chronic heart failure.

Authors:  Efstratios Vlaras; Konstantinos Giakoumidakis; Nikolaos V Fotos; Anastasia A Chatziefstratiou; Hero Brokalaki
Journal:  Pragmat Obs Res       Date:  2017-09-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.